Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Unknown primary tumours.

H F Hillen1

  • 1Department of Internal Medicine, University Hospital Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands. hhi@sint.azm.nl

Postgraduate Medical Journal
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Education and training in internal medicine in Europe.

Postgraduate medical journal·2001
Same author

Anginex, a designed peptide that inhibits angiogenesis.

The Biochemical journal·2001
Same author

Detection, treatment and outcome of axillary recurrence after axillary clearance for invasive breast cancer.

The British journal of surgery·2001
Same author

Thrombosis in cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2000
Same author

Cancer in the very elderly Dutch population.

Cancer·2000
Same author

Increased D-dimer levels correlate with binding of activated protein C, but not tissue factor expression, on peripheral blood monocytes in cancer patients.

American journal of hematology·2000
Same journal

Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials.

Postgraduate medical journal·2026
Same journal

Two cases of toxic epidermal necrolysis with severe ocular involvement treated with adjunctive tofacitinib.

Postgraduate medical journal·2026
Same journal

Diastolic dysfunction and diabetes: the DIADAD study-a retrospective cohort study from Liverpool.

Postgraduate medical journal·2026
Same journal

Care, cash, and proof: forensic accountability for war-related starvation.

Postgraduate medical journal·2026
Same journal

Response to traumatic injuries in polo players in England.

Postgraduate medical journal·2026
Same journal

Aids to venesection and parenteral drug administration in patients with difficult veins.

Postgraduate medical journal·2026
See all related articles

Unknown primary tumours (UPTs) present with metastatic cancer but no identifiable primary site. Identifying treatable subsets through diagnostic evaluation can improve patient prognosis beyond the typical four-month survival time.

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • Unknown primary tumours (UPTs) are metastatic cancers lacking a detectable primary origin.
  • UPTs exhibit aggressive biology, rapid progression, and atypical metastatic patterns.
  • Specific cytogenetic abnormalities, such as 1p deletion, are observed in UPTs.

Purpose of the Study:

  • To define unknown primary tumours (UPTs) and their characteristics.
  • To outline diagnostic strategies for UPTs.
  • To identify therapy-responsive subsets within UPTs for improved outcomes.

Main Methods:

  • Biopsy-proven metastatic cancer without a primary tumour identified.
  • Comprehensive diagnostic evaluation including pathology review, physical exam, and imaging (radiography, CT, mammography).

Related Experiment Videos

  • Analysis of clinicopathological criteria to define subsets.

    • Main Results:

    • UPTs are characterized by rapid progression and unusual metastases.
    • Cytogenetic abnormalities, notably 1p deletion, are associated with UPTs.
    • Diagnostic evaluation helps identify treatable patient subsets.

    Conclusions:

    • Therapy-responsive subsets of UPTs can be identified using clinicopathological criteria.
    • These identified subsets demonstrate a better prognosis compared to the general UPT population.
    • Targeted evaluation can lead to improved survival for specific UPT patients.